{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:58:49Z","timestamp":1786467529368,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s00408-020-00336-3","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T15:02:30Z","timestamp":1581519750000},"page":"355-360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Real-Life Study of Mepolizumab in Idiopathic Chronic Eosinophilic Pneumonia"],"prefix":"10.1007","volume":"198","author":[{"given":"Emeline","family":"Brenard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Pilette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dahlqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Colinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Schleich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Roufosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7133-1788","authenticated-orcid":false,"given":"Antoine","family":"Froidure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,12]]},"reference":[{"issue":"5","key":"336_CR1","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/j.jaip.2018.03.011","volume":"6","author":"J Allen","year":"2018","unstructured":"Allen J, Wert M (2018) Eosinophilic pneumonias. J Allergy Clin Immunol Pract 6(5):1455\u20131461. https:\/\/doi.org\/10.1016\/j.jaip.2018.03.011","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"336_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1055\/s-2006-939516","volume":"27","author":"E Marchand","year":"2006","unstructured":"Marchand E, Cordier JF (2006) Idiopathic chronic eosinophilic pneumonia. Semin Respir Crit Care Med 27(2):134\u2013141. https:\/\/doi.org\/10.1055\/s-2006-939516","journal-title":"Semin Respir Crit Care Med"},{"issue":"5","key":"336_CR3","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1378\/chest.105.5.1462","volume":"105","author":"H Hayakawa","year":"1994","unstructured":"Hayakawa H, Sato A, Toyoshima M, Imokawa S, Taniguchi M (1994) A clinical study of idiopathic eosinophilic pneumonia. Chest 105(5):1462\u20131466. https:\/\/doi.org\/10.1378\/chest.105.5.1462","journal-title":"Chest"},{"issue":"5","key":"336_CR4","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/00005792-199809000-00001","volume":"77","author":"E Marchand","year":"1998","unstructured":"Marchand E, Reynaud-Gaubert M, Lauque D, Durieu J, Tonnel AB, Cordier JF (1998) Idiopathic chronic eosinophilic pneumonia a clinical and follow-up study of 62 cases The Groupe d'Etudes et de Recherche sur les Maladies \"Orphelines\" Pulmonaires (GERM\"O\"P). Medicine (Baltimore) 77(5):299\u2013312. https:\/\/doi.org\/10.1097\/00005792-199809000-00001","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"336_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaci.2017.04.009","volume":"141","author":"PW Sullivan","year":"2018","unstructured":"Sullivan PW, Ghushchyan VH, Globe G, Schatz M (2018) Oral corticosteroid exposure and adverse effects in asthmatic patients. J Allergy Clin Immunol 141(1):110\u2013116. https:\/\/doi.org\/10.1016\/j.jaci.2017.04.009","journal-title":"J Allergy Clin Immunol"},{"key":"336_CR6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, Chanez P (2014) Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1403290","journal-title":"N. Engl J Med."},{"issue":"13","key":"336_CR7","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","volume":"371","author":"EH Bel","year":"2014","unstructured":"Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID, Investigators S (2014) Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 371(13):1189\u20131197. https:\/\/doi.org\/10.1056\/NEJMoa1403291","journal-title":"N Engl J Med"},{"issue":"6","key":"336_CR8","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1016\/j.jaci.2018.11.041","volume":"143","author":"J Steinfeld","year":"2019","unstructured":"Steinfeld J, Bradford ES, Brown J, Mallett S, Yancey SW, Akuthota P, Cid MC, Gleich GJ, Jayne D, Khoury P, Langford CA, Merkel PA, Moosig F, Specks U, Weller PF, Wechsler ME (2019) Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 143(6):2170\u20132177. https:\/\/doi.org\/10.1016\/j.jaci.2018.11.041","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"336_CR9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jaci.2012.07.055","volume":"131","author":"FE Roufosse","year":"2013","unstructured":"Roufosse FE, Kahn JE, Gleich GJ, Schwartz LB, Singh AD, Rosenwasser LJ, Denburg JA, Ring J, Rothenberg ME, Sheikh J, Haig AE, Mallett SA, Templeton DN, Ortega HG, Klion AD (2013) Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol 131(2):461\u2013467. https:\/\/doi.org\/10.1016\/j.jaci.2012.07.055","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"336_CR10","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1016\/j.jaip.2018.06.017","volume":"6","author":"M To","year":"2018","unstructured":"To M, Kono Y, Yamawaki S, Soeda S, Katsube O, Kishi H, To Y (2018) A case of chronic eosinophilic pneumonia successfully treated with mepolizumab. J Allergy Clin Immunol Pract 6(5):1746\u20131748. https:\/\/doi.org\/10.1016\/j.jaip.2018.06.017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"336_CR11","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa070812","volume":"358","author":"ME Rothenberg","year":"2008","unstructured":"Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ, Mepolizumab HESSG (2008) Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 358(12):1215\u20131228. https:\/\/doi.org\/10.1056\/NEJMoa070812","journal-title":"N Engl J Med"},{"issue":"4","key":"336_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.alit.2019.05.006","volume":"68","author":"Y Suzuki","year":"2019","unstructured":"Suzuki Y, Suda T (2019) Eosinophilic pneumonia: a review of the previous literature, causes, diagnosis, and management. Allergol Int 68(4):413\u2013419. https:\/\/doi.org\/10.1016\/j.alit.2019.05.006","journal-title":"Allergol Int"},{"issue":"4","key":"336_CR13","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.rmed.2015.01.019","volume":"109","author":"MA Judson","year":"2015","unstructured":"Judson MA, Chaudhry H, Louis A, Lee K, Yucel R (2015) The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis. Respir Med 109(4):526\u2013531. https:\/\/doi.org\/10.1016\/j.rmed.2015.01.019","journal-title":"Respir Med"},{"key":"336_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/all.12243","author":"S Nureki","year":"2013","unstructured":"Nureki S, Miyazaki E, Ishi T, Ito T, Takenaka R, Ando M, Kumamoto T (2013) Elevated concentrations of CCR7 ligands in patients with eosinophilic pneumonia. Allergy. https:\/\/doi.org\/10.1111\/all.12243","journal-title":"Allergy"},{"issue":"14","key":"336_CR15","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","volume":"380","author":"FL Kuang","year":"2019","unstructured":"Kuang FL, Legrand F, Makiya M, Ware J, Wetzler L, Brown T, Magee T, Piligian B, Yoon P, Ellis JH, Sun X, Panch SR, Powers A, Alao H, Kumar S, Quezado M, Yan L, Lee N, Kolbeck R, Newbold P, Goldman M, Fay MP, Khoury P, Maric I, Klion AD (2019) Benralizumab for PDGFRA-Negative hypereosinophilic syndrome. N Engl J Med 380(14):1336\u20131346. https:\/\/doi.org\/10.1056\/NEJMoa1812185","journal-title":"N Engl J Med"},{"key":"336_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13223-019-0348-z","volume":"15","author":"H Ortega","year":"2019","unstructured":"Ortega H, Lemiere C, Llanos JP, Forshag M, Price R, Albers F, Yancey S, Castro M (2019) Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial. Allergy Asthma Clin Immunol 15:37. https:\/\/doi.org\/10.1186\/s13223-019-0348-z","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"8","key":"336_CR17","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40273-018-0658-x","volume":"36","author":"RB McQueen","year":"2018","unstructured":"McQueen RB, Sheehan DN, Whittington MD, van Boven JFM, Campbell JD (2018) Cost-Effectiveness of biological asthma treatments: a systematic review and recommendations for future economic evaluations. Pharmacoeconomics 36(8):957\u2013971. https:\/\/doi.org\/10.1007\/s40273-018-0658-x","journal-title":"Pharmacoeconomics"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-020-00336-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00408-020-00336-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-020-00336-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T13:51:16Z","timestamp":1613051476000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00408-020-00336-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,12]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["336"],"URL":"https:\/\/doi.org\/10.1007\/s00408-020-00336-3","relation":{},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"value":"0341-2040","type":"print"},{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,12]]},"assertion":[{"value":"5 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors have no conflict of interest related to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The retrospective analysis of data from of patients who received mepolizumab for relapsing ICEP was approved by our ethical committee (study PNEU-ILD-02, approval number 2018\/15MAR\/116).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"As this was a retrospective study, signed informed consent from patients was waived, according to local regulation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}